Oncolytics Biotech Inc T.ONC

Immunogen Inc

[venture009]

The acquisition of Immunogen and it's ADC therapy is highligting this cancer therapy and the focus of large biotechs for future investments. Pfizer massive purchase of Seagen and now Abbvie's purchase of Immunogen. The question is BP now going to ignore virus's going forward and what doe this mean for ONC?

[fox7mf]

$10 billion. Nice.

[Noteable]

AbbVie plans to acquire ImmunoGen for $10.1 Billion, in a deal that would expand the Big Pharma’s presence in the oncology field and mark an exit for the 42-year-old Boston biotech.  ImmunoGen was founded in 1981. Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US

[Noteable]

The Phase 1/2 results of ONCYs GOBLET Cohort 4 that enrolled patients with advanced/metastatic unresectable SCCA  (anal cancer) who failed prior systemic therapy appear to be better than ImmunoGens results obtained from both of ImmunoGens Phase 2  SORAYA study to support accelerated approval by the FDA, and its followup Phase 3 MIRASOL

[Noteable]

Anti PD-1/PD-L1 single agent displayed a limited anti-tumor activity in un-selected patients with SCCA. Therefore, patients’ selection for immune checkpoint blockade still represents an unmet need. Selection is closely related to the urgency of more translational research to detect biomarkers that may predict who really benefit from PD-1/ PD-L1 blockade and identify driver mutations that may

[venture009]

Noteable, like too many of ONC trials the patient population is too small for statisical significanse. If they had 40+ patients in their trial with the same results, I believe we would be getting more recognition. I also wonder if this may be causing some hesitancy in a BP coming forward with an offer. 

[inthno]

Trial size does make a different for sure and I have always wondered why they did not continue on to the next stage of the panc trial. It would have been done now and so much more information. Someone had to make the call and for a major reason and it has now been over a year so what would be the reason. 

[Normandt]

This is the reality "Nov 2023, Within the GOBLET study's latest data on pelareorep in combination with the PD-L1 inhibitor atezolizumab (atezo) and chemotherapy is new data, including a 6-month progression-free survival (PFS) rate was 72.9%, and a 6-month overall survival (OS) rate of 82.1%—both significantly high for the industry standard.   A 72.9% PFS at 6 months is a

[Normandt]

Don't you find it very strange, that for cancer specialists "survival (PFS) rate was 72.9%, and a 6-month overall survival (OS) rate of 82.1%—both significantly high for the industry standard. But for venture; ..." population is too small for statisical significanse". And he repeats it almost every week, but he is supposed to be an oncy investor. And ithno said:  &

[Noteable]

" ... the technique of trying to misslead people is very subtle (very well known), but repetitive for one purpose" ..... would that purpose be to "trouble make" since such skeptics are usually not shareholders. 

[fox7mf]

I find it very strange that a deal hasn't happened yet...or maybe it has, at least I'm principle. In any event, the powers that be need a BP relationship if this ph 3 target of mid '24 is going to happen. Sign on the line that is dotted by EOY Matt. Inthno, or De_man on Stocktwits is a supporter of the science, is knowledgeable and is just very frustrated with the BD side of things. He

[Normandt]

""Inthno, or De_man on Stocktwits is a supporter of the science, is knowledgeable and is just very frustrated with the BD side of things. He's been with the company since '99...let him vent. Good luck Norm, and good posts btw."" Supporter of the science ??  so why he always inserts lies here and there interspersed with truths.... No matter how frustrated we are,

[inthno]

Hello Norm and I see you are back to attacking people again as you always do....All I did was question why the trial for panc did not continue on to the next phase as we really did not get an answer, I did not say it was a bad thing and was questioning who might have made the call whether it be the trial investigators, onc, or maybe Roche or a combo of the above....I think that is a reasonable

[Noteable]

If you think that what you post is a reasonable question, then why dont you pose your questions to ONCY rather than here? We cant answer for ONCY, so what do you expect posting here? Ive already responded to your devils advocate purpose - where you posted mistruths disguised as questions.

[Normandt]

ithno, I pointed out your lie below, but again you claim to have told the whole truth and just the truth...and I have done this many times in the past every time you have lied (you deny it every time). I repeat, I am not interested in conversing with you, precisely because you always attack others (sneak attacks), argue endlessly...but you do not accept that others do the same with you. You're

[Noteable]

ONCY's Phase 1/2  GOBLET basket study that included Cohort 4 results in SCCA (anal cancer) again demonstrates that pelareorep synergizes atezolizumab in the treatment of multiple cancers with results that are significant in the pursuit of an accelerated approval, and gives any Big Pharma the evidence needed to demonstrate pelareorep's effectiveness in combination with a CPI